In the exploratory analysis of the PALOMA-3 trial [40], evaluating predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant BC, it was found that median PgR H-scores were higher among long-term responders regardless of the treatment group. Here, PGR is linked to breast cancer.